Physician profile
David Gatof
NPI 1881613305
$11,006.04
in general payments reported to CMS, 2019-2025
36 companies · $1,998 in 2025
The $1,998 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,974 · 2020: $951 · 2021: $1,868 · 2022: $1,051 · 2023: $1,067 · 2024: $2,096 · 2025: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,776 · Grant: $335 · Education: $50.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,776.25 |
| Grant | $335.00 |
| Education | $50.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,416.35 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,114.03 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $729.67 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $634.30 | 2019-2025 | Stelara, Tremfya, Remicade |
| Gilead Sciences, INC. | $601.18 | 2019-2025 | |
| Pfizer INC. | $496.38 | 2019-2025 | |
| Celgene Corporation | $470.27 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $438.31 | 2022-2025 | Dupixent |
| Genzyme Corporation | $318.15 | 2022-2025 | |
| Ardelyx, INC. | $201.60 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $201.31 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $169.29 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $142.28 | 2019 | |
| Lilly USA, LLC | $136.53 | 2024-2025 | Omvoh |
| Ucb, INC. | $116.25 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $115.14 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $100.84 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $69.09 | 2019 | |
| Ethicon US, LLC | $52.83 | 2019 | |
| Nestle Healthcare Nutrition INC. | $49.67 | 2021 | |
| Intercept Pharmaceuticals, INC. | $49.52 | 2020-2024 | |
| Amgen INC. | $43.88 | 2022-2023 | Amjevita, Avsola |
| Shionogi INC | $42.18 | 2019 | |
| Aimmune Therapeutics, INC. | $40.24 | 2024 | |
| Braintree Laboratories, INC. | $38.54 | 2019-2020 | |
| Novo Nordisk INC | $33.79 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $32.13 | 2024 | Rebyota |
| Madrigal Pharmaceuticals | $28.52 | 2025 | Rezdiffra |
| Alfasigma USA, INC. | $26.08 | 2020 | |
| Shire North American Group INC | $23.52 | 2019 | |
| Exact Sciences Corporation | $17.45 | 2024 | |
| Alexion Pharmaceuticals, INC. | $16.12 | 2019 | |
| Redhill Biopharma INC. | $15.46 | 2021 | |
| Allergan, INC. | $12.67 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gatof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.